Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Valerio Therapeutics's Enterprise Value is €397.12 Mil.
Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52 Mil. Therefore, Valerio Therapeutics's EV-to-FCF for today is 762.23.
The historical rank and industry rank for Valerio Therapeutics's EV-to-FCF or its related term are showing as below:
LTS:0NWK'
s EV-to-FCF Range Over the Past 10 Years
Min: -10.91 Med: -2.73 Max: 597.35
Current: 597.35
During the past 13 years, the highest EV-to-FCF of Valerio Therapeutics was 597.35. The lowest was -10.91. And the median was -2.73.
LTS:0NWK's EV-to-FCF is ranked worse than 97.34% of 338
companies
in the Biotechnology industry
Industry Median: 15.175
vs LTS:0NWK: 597.35
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Valerio Therapeutics's PE Ratio (TTM) for today is calculated as:
Valerio Therapeutics's share price for today is €0.77.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.009.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Valerio Therapeutics EV-to-FCF Related Terms
Valerio Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Valerio Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0NWK vs VRTX, REGN, ALNY: EV-to-FCF Comparison
For the Biotechnology subindustry, Valerio Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valerio Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valerio Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Valerio Therapeutics's EV-to-FCF falls into.
Valerio Therapeutics's current Enterprise Value is €397.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Valerio Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €0.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valerio Therapeutics (LTS:0NWK) has a EV-to-FCF of 762.23 as of Jul. 23, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Valerio Therapeutics and its competitors. According to the industry distribution chart, Valerio Therapeutics ranks #329 out of 338 companies in the Biotechnology industry, placing it in the top 97.3%.
Is Valerio Therapeutics' EV-to-FCF too high?
Valerio Therapeutics' current EV-to-FCF is 762.23. The Biotechnology industry median EV-to-FCF is 15.18. Valerio Therapeutics' value of 762.23 is 4922.9% above this industry median. Based on the distribution chart, Valerio Therapeutics ranks #329 out of 338 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valerio Therapeutics has a GF Score™ of 32/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Valerio Therapeutics' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Valerio Therapeutics ranks #329 out of 338 companies for EV-to-FCF. This places Valerio Therapeutics in the lower half of its industry. The industry median EV-to-FCF is 15.18. Valerio Therapeutics' value of 762.23 is 4922.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 15.18, based on 338 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Valerio Therapeutics's current EV-to-FCF of 762.23 is 4922.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Valerio Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 15.18 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Valerio Therapeutics's current EV-to-FCF is 762.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valerio Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Valerio Therapeutics (LTS:0NWK) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.07, compared to a current price of €0.77 — trading 1000% above its estimated fair value. The current EV-to-FCF is 762.23 and 4922.9% above the Biotechnology industry median of 15.18. Valerio Therapeutics' overall GF Score™ is 32/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Valerio Therapeutics (LTS:0NWK), the current EV-to-FCF is 762.23 as of Jul. 23, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Valerio Therapeutics (LTS:0NWK) Overvalued in 2026?
Based on GuruFocus' analysis, Valerio Therapeutics stock appears to be overvalued.
The current stock price of €0.77 is trading 1000% above its estimated GF Value™ of €0.07.
GuruFocus considers Valerio Therapeutics to be Significantly Overvalued.
Key valuation signals for LTS:0NWK:
EV-to-FCF: 762.23
GF Value™: €0.07 vs. price of €0.77 (1000% above fair value)
Industry Position: 4922.9% above the Biotechnology median (#329 of 338)
No single metric tells the full story. See the LTS:0NWK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Valerio Therapeutics is a clinical-stage biotechnology company developing drug candidates using three proprietary platforms: the PlatON platform, DecoyTAC, and the V-Body platform, generating single-domain therapeutic antibodies. The Company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners. Its pipeline includes Metabolic Diseases, Immunology & Inflammatory.
32GF Score
Get the complete analysis for LTS:0NWK
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0NWK has been successfully added to your 
